top of page
Search

SGLT2 vs GLP-1 for Kidney Disease: What the Trial Data Actually Shows



If you have chronic kidney disease, or you love someone who does, you have probably heard about SGLT2 inhibitors and GLP-1 receptor agonists. These two drug classes are reshaping how we protect kidneys, and the clinical trial data behind them is striking. But which one should you ask about first? And what role does something as simple as sleep play in kidney protection?

Key Takeaways


  • SGLT2 inhibitors (like dapagliflozin) reduced kidney failure risk by 39% in the DAPA-CKD trial, which was stopped early because the benefit was so clear. Long-term modeling suggests a potential delay of 6.6 years to kidney failure.

  • GLP-1 receptor agonists (like semaglutide) reduced major kidney events by 24% and all-cause death by 20% in the FLOW trial, also stopped early for benefit.

  • Sleep regularity may be a stronger predictor of mortality than sleep duration. The most consistent sleepers in a study of over 60,000 adults had up to 48% lower all-cause mortality.


Overview


We Are Still Missing Early Kidney Disease


Chronic kidney disease affects roughly 1 in 7 US adults. As many as 9 out of 10 don't know they have it. A 2026 study published in Kidney International, based on data from 1.1 million adults and nearly 7 million kidney function tests, found that standard eGFR cutoffs can miss patients at serious risk (Yang et al., 2026).


The researchers built percentile-based reference charts for kidney function by age and sex. Their findings were sobering. A 55-year-old woman with an eGFR of 80, a value most clinicians would call normal, actually falls at the 10th percentile for women her age. That corresponds to a three-fold higher risk of eventually needing dialysis. Among people with eGFR above 60 but below the 25th percentile for their age, only about one in four had ever received a urine albumin test, the test that detects early kidney damage.


SGLT2 Inhibitors: The Foundation for Kidney Protection


The landmark DAPA-CKD trial, published in the New England Journal of Medicine, enrolled over 4,300 patients with CKD, with and without diabetes (Heerspink et al., 2020). Dapagliflozin (Farxiga) reduced the primary composite kidney outcome by 39% compared to placebo: 9.2% versus 14.5%. All-cause mortality dropped from 6.8% to 4.7%, a 31% reduction. The trial was stopped early because the independent data monitoring committee determined it would be unethical to continue the placebo arm.


The number needed to treat was 19, meaning that for every 19 patients treated with dapagliflozin, one major kidney event was prevented. Long-term modeling published in Nephrology Dialysis Transplantation estimated that dapagliflozin may delay kidney failure by approximately 6.6 years (NDT, 2024). These benefits held whether patients had type 2 diabetes or not.


GLP-1 Receptor Agonists: The Reinforcements


The FLOW trial, also published in the New England Journal of Medicine, tested semaglutide (Ozempic) in 3,533 patients with type 2 diabetes and CKD (Perkovic et al., 2024). Semaglutide reduced major kidney disease events by 24%. Major cardiovascular events were 18% lower. All-cause death was 20% lower. This trial was also stopped early for benefit.


Semaglutide slowed the annual eGFR decline by 1.16 ml per minute and reduced urine albumin by 38%. The number needed to treat to prevent one death over three years was 39.


How Do They Compare?


A large comparative-effectiveness study published in JAMA Internal Medicine analyzed approximately 36,000 patients on SGLT2 inhibitors versus 19,000 on GLP-1 receptor agonists in Denmark (Jensen et al., 2026). The 5-year risk of CKD was about 7% with SGLT2 inhibitors versus just over 8% with GLP-1s, suggesting a slight edge for SGLT2 inhibitors on pure kidney outcomes. However, the GLP-1 group had slightly lower albuminuria and slightly lower mortality.


In my clinical practice, I think of these two drug classes as teammates rather than competitors. For most patients with CKD, the approach is to start with an SGLT2 inhibitor as the kidney-protective foundation, then consider adding a GLP-1 if the patient also has obesity, needs additional blood sugar control, or has elevated cardiovascular risk.


Sleep: The Free Longevity Drug


A nationwide analysis in SLEEP Advances found that insufficient sleep ranked just behind smoking as a predictor of shortened life expectancy across over 3,000 US counties (McAuliffe et al., 2025).


But the more surprising finding comes from research on sleep regularity. A 2024 study in the journal SLEEP tracked over 60,000 adults with wrist-worn accelerometers and found that sleep regularity is a stronger predictor of mortality risk than sleep duration (Windred et al., 2024). The most regular sleepers had up to 48% lower all-cause mortality. A 2025 study of 72,269 UK adults confirmed that irregular sleepers had higher rates of heart attack, stroke, and heart failure, even when they slept enough hours (Chaput et al., 2025).


A proof-of-concept study showed that just two weeks of bedtime regularization decreased systolic blood pressure by 4 to 5 mmHg in people with hypertension (Thosar et al., 2025). For CKD patients with high blood pressure, that is a clinically meaningful reduction from a zero-cost intervention.


A systematic review of sleep hygiene strategies specifically in CKD patients found that exercise earlier in the day and relaxation techniques before bed had the strongest effects on sleep quality in kidney disease.


What You Can Do


  • Know your kidney numbers. Ask your doctor for your eGFR, urine albumin-creatinine ratio, blood pressure, and A1c. Ask what your 5-to-10-year kidney failure risk is and how to lower it. A "normal" eGFR can still mean elevated risk for your age.

  • Ask about SGLT2 inhibitors and GLP-1s. If you have CKD with or without diabetes, ask whether an SGLT2 inhibitor is appropriate for you. If you also have obesity or elevated cardiovascular risk, ask whether adding a GLP-1 could provide additional benefit.

  • Prioritize sleep regularity over sleep duration. Pick a consistent bedtime and wake time, seven days a week. Aim for 7 to 9 hours. Screen for sleep apnea if you snore or feel excessively tired. Try a 12-hour overnight fast (for example, 7:30 pm to 7:30 am). Add a wind-down routine with relaxation techniques before bed.

  • Protect your muscle. If you are on a GLP-1 and have CKD, pair your medication with adequate protein intake (supervised by your nephrologist and dietitian) and resistance training two to three times per week.

  • Talk to your doctor before making changes. Medication decisions depend on your individual kidney function, potassium levels, blood pressure, and other factors. Use this information to have a better conversation, not to self-prescribe.


The Bottom Line


We are living in the best era for kidney protection in human history. SGLT2 inhibitors and GLP-1s have trial-level evidence showing they slow kidney disease, reduce cardiovascular events, and extend life. Sleep regularity, a free intervention, may be one of the most underused tools for longevity. The question is not whether these tools exist. The question is whether you and your doctor are using them.


Scientific References

  1. Heerspink, H. J. L., et al. (2020). Dapagliflozin in patients with chronic kidney disease. New England Journal of Medicine, 383(15), 1436-1446. https://doi.org/10.1056/NEJMoa2024816

  2. Perkovic, V., et al. (2024). Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes. New England Journal of Medicine, 391(2), 109-121. https://doi.org/10.1056/NEJMoa2403347

  3. Jensen, S. K., et al. (2026). SGLT2 inhibitors vs GLP-1 receptor agonists for kidney outcomes. JAMA Internal Medicine. https://doi.org/10.1001/jamainternmed.2025.xxxxx

  4. Yang, Y., et al. (2026). Population-based estimated glomerular filtration rate distributions and associated health outcomes. Kidney International. https://doi.org/10.1016/j.kint.2025.11.009

  5. McAuliffe, K. E. S., et al. (2025). Sleep insufficiency and life expectancy at the state-county level in the United States, 2019-2025. SLEEP Advances. https://doi.org/10.1093/sleepadvances/zpae091

  6. Windred, D. P., et al. (2024). Sleep regularity is a stronger predictor of mortality risk than sleep duration: A prospective cohort study. SLEEP, 47(1), zsad253. https://doi.org/10.1093/sleep/zsad253

  7. Chaput, J.-P., et al. (2025). Sleep regularity and major adverse cardiovascular events: A device-based prospective study in 72,269 UK adults. Journal of Epidemiology & Community Health, 79(4), 257-264. https://doi.org/10.1136/jech-2024-222795

  8. Thosar, S. S., et al. (2025). Bedtime regularization as a potential adjunct therapy for hypertension: A proof-of-concept study. SLEEP Advances, 6(4), zpaf082. https://doi.org/10.1093/sleepadvances/zpaf082

  9. Kalkanis, A., et al. (2025). Sleep regularity as an important component of sleep hygiene: A systematic review. Sleep Medicine Reviews. https://doi.org/10.1016/j.smrv.2025.101956

  10. Furth, S. L., et al. (2025). The relationship between obesity and chronic kidney disease: Conclusions from a KDIGO Controversies Conference. Kidney International. https://doi.org/10.1016/j.kint.2025.07.031

  11. Wang, W., et al. (2024). Associations of semaglutide with incidence and recurrence of alcohol use disorder in real-world population. Nature Communications, 15(1), 4548. https://doi.org/10.1038/s41467-024-48780-6

  12. Long-term effects of dapagliflozin in chronic kidney disease: A time-to-event analysis. (2024). Nephrology Dialysis Transplantation, 39(12), 2040. https://doi.org/10.1093/ndt/gfae228


Support the Mission


Your support keeps this evidence-based health education free for everyone. -> Donate Here Thank you.


Get Free Weekly Health Tips


Join thousands of readers who get evidence-based insights on kidney health, longevity, and disease prevention delivered to their inbox. -> Subscribe to the Newsletter


Medical Disclaimer


This article is for educational purposes only and is not medical advice, diagnosis, or treatment. Always consult your healthcare provider before making changes to your health routine. The views expressed are Dr. Hashmi's personal professional opinions and do not represent any employer or affiliated organization.

 
 
 

Comments

bottom of page